Research and Markets has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering.
The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market.
Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc.
Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd.
Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.'
For more information visit http://www.researchandmarkets.com/research/r75h94/nanotechnology
Source: http://www.researchandmarkets.com